Based on this understanding, immune checkpoint blockade (ICB) therapies, particularly targeting PD-1/PD-L1, have shown promise in partially reversing the exhaustion of CD8+ T cells and, consequently, controlling tumor progression. The gene discussed is CD8A; the disease is neoplasm.